| SNDK |
Report |
FQ4'26 Revenue |
BEAT |
pred ~$8.4B vs. cons ~$8.3B |
MEDIUM |
| SNDK |
Report |
FQ4'26 Non-GAAP EPS |
BEAT |
pred ~$35.00 vs. cons ~$34.00 |
MEDIUM |
| SNDK |
Report |
FQ4'26 Non-GAAP Gross Margin |
BEAT |
pred ~81.5% vs. cons ~80.0% |
MEDIUM |
| SNDK |
Guide |
FQ1'27 Revenue guide (midpoint) |
BETTER |
guide ~$9.0B vs. cons ~$8.7B (FQ1'27) |
LOW |
| SNDK |
Guide |
FQ1'27 Gross Margin guide |
BETTER |
guide ~81% vs. cons ~79% (FQ1'27) |
LOW |
| SNDK |
Guide |
FQ1'27 Non-GAAP EPS guide |
BETTER |
guide ~$38 vs. cons ~$36 (FQ1'27) |
LOW |
| SNDK |
Guide |
NBM contracted-bit coverage of FY2027 (durability signal) |
BETTER |
guide ~50% of FY27 bits vs. prior >33% (FY2027) |
MEDIUM |
| SNDK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+7.0% |
— |
LOW |
| SNDK |
Return |
5-day cumulative residual |
+2.0% (FADE) |
Likely beat-and-raise on record revenue/margins triggers an oversold relief pop off the ~55% July drawdown (stock already bounced from ~$1,016 to ~$1,428 into the print). But consensus already embeds a beat-and-raise, and the market's core worry is out-period ASP/margin normalization (CXMT/China NAND oversupply, peak-cycle 2028). Even a strong near-term guide leaves 2H-CY26/FY28 estimates exposed to implicit cuts, so the initial spike fades as the cyclical-peak narrative and profit-taking reassert; ±25% implied vol makes direction low-conviction. |
LOW |